• India
More

    Bharat Biotech starts human trial for COVAXIN

    Must Read

    4679 Ramdesivir injections provided to private hospitals in four days

    Remedisivir injections useful in the treatment of corona have been distributed to private hospitals in last four...

    Covid 19 cases reached 32738 in Vadodara after 422 new cases on Sunday

    Total 227 discharged from hospital taking the total to 28717 The number of positive...

    Monis Khan enters strong in Bollywood with mythological thriller Consequence Drama

    Monis Khan enters strong in Bollywood with Consequence Karma, a mythological thriller. The actor had a fair...

    The human trial of Bharat Biotech’s anti-COVID-19 vaccine Covaxin began at Rohtak’s Post-Graduate Institute of Medical Sciences on Friday, Haryana Health Minister Anil Vij said.

    The minister also said the vaccine has been administered to three persons who have shown no adverse effect to it.

    Doctors at the Rohtak PGIMS, meanwhile, told reporters that three volunteers were administered the vaccine as part of the first phase of the clinical trial.

    They said the process might take six months, but over the next two-three months, the effect of the vaccine would be assessed from the antibodies generated and any adverse reaction caused, if any.

    The volunteers are in the age group of 30 to 40 years.

    The vaccine will now be administered to ten persons who like the three would be observed on a regular basis.

    In the second phase, more vaccine candidates will be enrolled and the vaccine dosage would also be increased, they said.

    Bharat Biotech got the country’s drug regulator’s approval to start clinical trials of its anti-Corona vaccine Covaxin recently.

    There are over seven anti-corona vaccines at various stages of development in the country with two of them having received the drug regulator’s go-ahead to start the human clinical trials of their vaccines.

    Earlier on Wednesday, drug firm Zydus had said it has started human clinical trials of its COVID-19 vaccine candidate ZyCoV-D. In this phase of trials, the company will be enrolling over 1,000 subjects across multiple clinical study sites in India, it had said in a regulatory filing.

    Zydus had got the approval a few days after India’s first indigenous COVID-19 vaccine candidate COVAXIN, developed by Bharat Biotech in collaboration with Indian Council of Medical Research and National Institute of Virology, got the nod for human clinical trials from the Drug Controller General of India.

    LEAVE A REPLY

    Please enter your comment!
    Please enter your name here

    This site uses Akismet to reduce spam. Learn how your comment data is processed.

    Latest News

    PM Narendra Modi asks for maximum jabs, zero wastage during Tika Utsav

    Prime Minister Narendra Modi appealed for the maximum number of Covid-19 vaccine jabs to be given during...

    Covid 19 cases reached 32738 in Vadodara after 422 new cases on Sunday

    Total 227 discharged from hospital taking the total to 28717 The number of positive in Vadodara reached 32738 after...

    Monis Khan enters strong in Bollywood with mythological thriller Consequence Drama

    Monis Khan enters strong in Bollywood with Consequence Karma, a mythological thriller. The actor had a fair share of hardwork to give...

    OSD Dr. Vinod Rao visited Dhiraj and Parul hospitals

    Review work progress regarding beds capacity and liquid oxygen setup OSD Dr. Vinod Rao visited Dhiraj Hospital and reviewed...

    Team from central goverment visited Vadodara in view of rising covid cases

    Appreciate the efforts of administration in proactive managment of facilities A team from central goverment visited Vadodara in view...

    More Articles Like This

    - Advertisement -